Early Diagnosis Advisory Group (EDAG)
The Early Diagnosis Advisory Group (EDAG) is a policy-focused funding and advisory committee responsible for the oversight, development, review, and management of a portfolio of research that aims to significantly add to the evidence base that will impact on policy and practice for earlier cancer diagnosis.
EDAG provides short-term project grants that use innovative, multidisciplinary and rapid approaches (using pre-existing data sources where necessary) to build the policy-related evidence base for earlier cancer diagnosis.
Applications for funding should be made in response to specific open calls for research advertised on the EDAG webpage.
The group does not fund biomedical research, such as the identification of biomarkers or new screening techniques, which should instead be directed to Population Research Committee.
How proposals are judged
The Committee meets up to three times a year for either strategic discussion or to assess funding applications. Applications are judged on the basis of scientific excellence, potential impact on policy and practice, strategic importance and also from the expert external peer review collated for each grant application.
Chair of EDAG
Prof Peter Sasieni - Queen Mary, University of London.
Vice-chair of EDAG
Prof Paul Aylin (Vice-chair) - Imperial College London
Dr Sally Vernon - Public Health England / National Cancer Registration Service
Dr Jo Waller - University College London
Dr Lilian Pittam - Patient representative
Dr Marjolein Berger - University Medical Center Groningen, The Netherlands
Mr John Butler - Royal Marsden Hospital, London
Prof Paul Little - University of Southampton
Mr Alan Chant - Patient representative
Dr Yoryos Lyratzopoulos – University College London
Dr Mick Peake - University Hospitals Leicester
Dr Gerry Richardson - University of York
Funded projects and outputs
Find out more about the research we fund